Back to top
more

Novavax (NVAX)

(Real Time Quote from BATS)

$13.21 USD

13.21
8,796,848

+0.31 (2.40%)

Updated May 16, 2024 12:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novavax (NVAX) Stock Moves -0.67%: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $0.57, marking a -0.67% move from the previous day.

Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $0.59, marking a +1.57% move from the previous day.

Novavax (NVAX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $0.53, marking a +0.21% move from the previous day.

Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

    Is a Beat in Store for Catabasis (CATB) This Earnings Season?

    by Zacks Equity Research

    Catabasis (CATB) progresses with DMD candidate, edasalonexent. However, operating expenses are likely to be lower.

    What's in the Cards for Novavax (NVAX) This Earnings Season?

    by Zacks Equity Research

    Novavax (NVAX) is expected to provide updates on its lead vaccine candidate, Resvax when it reports fourth-quarter 2018 results.

    Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

    by Zacks Equity Research

    Novavax (NVAX) closed the most recent trading day at $2.19, moving -0.45% from the previous trading session.

    Novavax (NVAX) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    In the latest trading session, Novavax (NVAX) closed at $2.30, marking a +0.44% move from the previous day.

    Is Novavax (NVAX) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Is (NVAX) Outperforming Other Medical Stocks This Year?

    Novavax (NVAX) Reports Q3 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Novavax (NVAX) delivered earnings and revenue surprises of 0.00% and -23.91%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

    Novavax (NVAX) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    Novavax (NVAX) closed at $1.92 in the latest trading session, marking a +1.05% move from the prior day.

    What's in the Cards for Novavax (NVAX) This Earnings Season?

    by Zacks Equity Research

    Investors are looking forward to Novavax's (NVAX) updates on its pipeline candidates when it reports third-quarter 2018 results.

    Will Novavax (NVAX) Report Negative Earnings Next Week? What You Should Know

    by Zacks Equity Research

    Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?

    by Zacks Equity Research

    Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

      Novavax (NVAX) Catches Eye: Stock Jumps 7.6%

      by Zacks Equity Research

      Novavax (NVAX) shares rose nearly 8% in the last trading session, amid huge volumes.

        Is the Options Market Predicting a Spike in Novavax (NVAX) Stock?

        by Zacks Equity Research

        Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

          Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates

          by Zacks Equity Research

          Novavax (NVAX) delivered earnings and revenue surprises of 0.00% and 4.85%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

            Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?

            by Zacks Equity Research

            Is Novavax, Inc. (NVAX) Outperforming Other Medical Stocks This Year?

              Debapriya Chakraborty headshot

              Pick 3 Biotech Money-Spinning Bets Amid Market Instability

              by Debapriya Chakraborty

              The drugs/biotech sector has been down since the past month, reeling under broader market pressures. Only a few good stocks however, remain out of this rut.

                Novavax (NVAX) in Focus: Stock Moves 8.3% Higher

                by Zacks Equity Research

                The shares of Novavax (NVAX) rose over 8% yesterday.

                  Benjamin Rains headshot

                  3 Stocks Under $10 That Surged Today

                  by Benjamin Rains

                  Here at Zacks, we encourage investors to follow our proven stock-picking system, which places a great deal of emphasis on earnings estimate revisions in order to find winning stocks. However, we also always seek to cover stocks, big and small, that are making noteworthy moves.

                    Options Traders Expect Huge Moves in Novavax (NVAX) Stock

                    by Zacks Equity Research

                    Novavax (NVAX) needs investors to pay close attention to the stock based on moves in the options market lately.

                      Novavax, Inc. (NVAX) Jumps: Stock Rises 8.4%

                      by Zacks Equity Research

                      Novavax, Inc. (NVAX) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.

                        Zacks.com featured highlights: Ardelyx, Novavax, BioScrip, Layne Christensen and Resonant

                        by Zacks Equity Research

                        Zacks.com featured highlights: Ardelyx, Novavax, BioScrip, Layne Christensen and Resonant

                          Swarup Gupta headshot

                          5 Breakout Stocks Offering Phenomenal Returns

                          by Swarup Gupta

                          This approach involves homing in on stocks trading within a tight range and buying them when they step out of this band.